Replimune Group Inc

Replimune’s shares tumble 10% after the FDA blocks its skin‑cancer therapy RP1, highlighting the need for controlled trials and exposing investor risk.

Replimune’s second FDA rejection of its RP1 melanoma therapy forces a strategic overhaul—stock drops, layoffs hit, and the company must reshape trials or pivot its pipeline for survival.

Replimune Group’s PDUFA update and breakthrough SITC data boost analyst confidence in its RP1 oncolytic therapy, positioning the company for FDA approval and potential market upside.

Replimune Group Inc. is facing a critical moment as a class action lawsuit is filed, potentially impacting the company’s financial health and stock performance, while also presenting an opportunity for investors to recover losses.

Replimune Group Inc., a biotechnology company, is facing multiple class action lawsuits from investors alleging securities fraud and misrepresentation, amid the company’s financial struggles.

Replimune Group Inc.’s stock plummeted 75% after the FDA rejected its application for a skin cancer treatment, sparking a wave of analyst downgrades and market volatility.

Replimune Group Inc.’s stock price plummeted 75% after the FDA rejected its experimental skin cancer treatment application, leading to analyst downgrades and market turbulence.

Replimune Group Inc.’s stock has experienced significant fluctuations, raising questions about the company’s financial health and strategic direction amidst its pioneering work in oncolytic immunotherapy.

Replimune Group Inc’s stock price surged 10.9% to $8.14, driven by growing investor confidence in the company’s oncolytic immunotherapy treatments and the expanding intra-tumoral cancer therapies market.